Please use this identifier to cite or link to this item: https://doi.org/10.1097/IJG.0b013e31818fb434
Title: The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension
Authors: Manni, G.
Denis, P.
Chew, P. 
Sharpe, E.D.
Orengo-Nania, S.
Coote, M.A.
Laganovska, G.
Volksone, L.
Zeyen, T.
Filatori, I.
James, J.
Aung, T. 
Keywords: Brinzolamide
Dorzolamide
Fixed combination
Glaucoma
IOP
Timolol
Issue Date: Apr-2009
Citation: Manni, G., Denis, P., Chew, P., Sharpe, E.D., Orengo-Nania, S., Coote, M.A., Laganovska, G., Volksone, L., Zeyen, T., Filatori, I., James, J., Aung, T. (2009-04). The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Journal of Glaucoma 18 (4) : 293-300. ScholarBank@NUS Repository. https://doi.org/10.1097/IJG.0b013e31818fb434
Abstract: PURPOSE: This study compared the intraocular pressure (IOP)-lowering efficacy of 2 fixed combination products, brinzolamide 1%/timolol 0.5% suspension (Azarga, Brinz/Tim) and dorzolamide 2%/timolol 0.5% solution (Dorz/Tim), in patients with open-angle glaucoma or ocular hypertension who required a change in therapy due to elevated IOP while receiving IOP-lowering medication. METHODS: This was a one-year, multicenter, randomized, double-masked, active-controlled, parallel-group trial of Brinz/Tim and Dorz/Tim. IOP assessments were taken at 8 and 10 AM at week 2 and months 3 and 9, and at 8 AM, 10 AM, and 4 PM at months 6 and 12. Primary efficacy was a noninferiority comparison of mean IOP at the three month 6 time points. RESULTS: Of the 437 patients enrolled, 220 dosed Brinz/Tim whereas 217 dosed Dorz/Tim twice daily. Brinz/Tim produced IOP-lowering efficacy comparable to Dorz/Tim, with the upper 95% confidence limits for the differences between groups within +1.5 mm Hg at all assessment times, including the month 6 primary efficacy time points, establishing noninferiority. Differences in means numerically favored Brinz/Tim at 9 of 12 study visits and times. The IOP reductions ranged from 7.2 to 9.2 mm Hg for Brinz/Tim and from 7.4 to 8.9 mm Hg for Dorz/Tim. Although a similar overall safety profile was observed between the 2 treatment groups, Brinz/Tim showed significantly less ocular irritation (2.7% vs. 10.6%; P=0.0009) than Dorz/Tim. CONCLUSIONS: Brinz/Tim suspension provides statistically significant and clinically relevant IOP-lowering efficacy that is noninferior to Dorz/Tim. Additionally, Brinz/Tim affords an ocular comfort advantage compared with Dorz/Tim. © 2009 Lippincott Williams & Wilkins, Inc.
Source Title: Journal of Glaucoma
URI: http://scholarbank.nus.edu.sg/handle/10635/130073
ISSN: 10570829
DOI: 10.1097/IJG.0b013e31818fb434
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.